
In the second part of a two-part interview, Paz Vellanki of Precision for Medicine explains which confirmatory evidence can support a single-trial approval and why she expects FDA's rare disease framework to last.
James M. Cornelius, who has served as interim chief executive for the past eight months, has been elected chief executive officer of Bristol-Myers Squibb Company (New York, NY, www.bms.com) with a term through the date of the company's annual meeting of stockholders in 2009.
James M. Cornelius, who has served as interim chief executive for the past eight months, has been elected chief executive officer of Bristol-Myers Squibb Company (New York, NY,







